Business Wire

Mayor of London Announces New London-Japan Partnership Targeting Devastating Neurodegenerative Diseases

Del

A new London-Japan partnership to understand why devastating neurodegenerative diseases such as Parkinson’s or Motor Neurone Disease develop and how they can be disrupted will be announced today by the Mayor of London Boris Johnson during his trade mission to Japan.

The new partnership between Takeda Pharmaceutical Company Limited (TSE: 4502), Japan’s largest pharmaceutical company, and UCL (University College London), regularly ranked as one of the world’s top 10 universities, focuses on identifying and understanding the role genes and genetic mutations play in these diseases so that they can be targeted with more effective new treatments.

The partnership will see Takeda and UCL scientists working side by side across a range of pre-clinical drug discovery areas, including bioinformatics, molecular biology and pharmacology. The collaboration has also received funding support from the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre.

Takeda is a major international investor in London’s life sciences industry, with a development centre in central London as well as a presence in other areas of England, including its research site in Cambridge, which initiated the collaboration with UCL to enhance its work to discover treatments for neurodegenerative diseases. Takeda Cambridge is also actively researching novel therapies in multiple therapeutic areas

The announcement coincides with a new report from PwC’s Strategy& released today which shows that Japan is the second largest overseas investor in the life sciences sector of England’s greater south east region, with £160m invested over the last 10 years. The report, which is based on interviews with senior figures in nine leading Japanese pharmaceutical companies, finds that the top reasons cited for the region’s popularity is the presence of international talent and top universities, its strong ecosystem of large and small companies, and its favourable business environment, from labour laws to intellectual property.

Read the full report here: http://medcityrb.staging.wpengine.com/wp-content/uploads/2015/09/Collaborating-for-success.pdf

The partnership and report are unveiled by the Mayor of London Boris Johnson at BioJapan, Asia’s leading biotechnology event, attracting thousands of representatives from some 700 of the world’s leading bioscience companies every year. He will give the keynote speech at the opening night networking reception and celebrate the world-leading life sciences sector of London and the greater south east - home to 1,896 life sciences companies generating £16.6 billion annually and employing 62,855 people UK-wide.*

The Mayor is joined at BioJapan by MedCity, an organisation that he launched in April 2014 to promote and lead the growth of the world-leading life sciences cluster of London and the greater south east.

The Mayor of London Boris Johnson said:

“London is a world-leading scientific city with some of the greatest universities in the world, at the very forefront of the drive to understand terrible, life-altering diseases and how they can be stopped. Working with global partners is a crucial part of turning research breakthroughs into better treatments, and I’m absolutely delighted that Takeda is deepening its commitment to London through this partnership.”

Dr. Tetsuyuki Maruyama, General Manager of Takeda's Pharmaceutical Research Division, said:

"At Takeda, we work with partners to accelerate innovation. We are looking forward to collaborating with UCL’s world-class researchers. This cooperation will help us to identify and validate novel therapeutic pathways in central nervous system diseases, which is one of Takeda’s core therapeutic areas – ultimately leading to new treatments for patients suffering from neurodegenerative disorders.”

UCL’s agreement with Takeda complements its alliance with Japanese pharmaceutical company Eisai, launched three years ago to develop new ways of treating neurological diseases such as Alzheimer’s and Parkinson’s.

UCL President & Provost Professor Michael Arthur said:

“Our alliance with Eisai was a crucial step in UCL’s drive to develop new therapies for neurodegeneration. This drive is mirrored in other fields of research and is exemplified by the collaborative nature of UCL’s research, particularly in partnering with industry. This partnership between UCL and Takeda is a very exciting development. UCL has a long and successful track record of working with companies in Japan and we are keen to build on this further across all areas of research.”

MedCity will use its presence at BioJapan to launch a major new drive to promote cell therapy collaborations between the UK and Japan, in partnership with London & Partners and the GREAT Britain campaign**.

The campaign includes a new report and video showcasing the excellence of London and the Greater South East in cell therapy and regenerative medicine, with contributions from companies including Takeda and Pfizer, research centres including Oxford and Cambridge universities, Osaka University, University College London, King’s College London and the Cell Therapy Catapult, and UK Minister for Life Sciences George Freeman.

Dr Eliot Forster, Executive Chair of MedCity, says:

“I’m absolutely delighted to be bringing some of our most exciting biotechs to Japan to showcase the innovative, diverse ways that cell therapies are being developed and commercialised in the UK. With Japan also having such a strong track record and commitment to this field, there are huge opportunities for us to work together to fast-track a potentially game-changing new science.”

-ends-

Mayor of London photo and filming opportunities

Media not registered for BioJapan should contact Abigail Smith for access – details below.

Wednesday 14 October
16.30
Photocall with the Mayor of London at the MedCity stand
Booth C-14
BioJapan, Pacifico Yokohama

Wednesday 14 October
17.30
Mayor of London speech at BioJapan networking reception
Osanbashi Hall, Yokohama

Notes to editors

*Research produced by Trampoline Systems and SQW for the Greater London Authority.

**Stem cells are cells that have the ability to renew themselves by dividing, and have the potential to develop into many different cell types. In many tissues they act as an internal repair system, dividing without limit to replenish other cells. This gives them enormous potential for treating a wide range of diseases and for repairing damaged organs. Cell therapy research is pushing forward our understanding of how they work and how they can be used in cell-based therapies or regenerative medicine.

PwC report details

Collaborating for success in Cambridge, London, Oxford, and South East of England - the view of Japanese pharma was produced for MedCity by PwC's Strategy& in the UK and PwC in Japan.

Read the report here: http://medcityrb.staging.wpengine.com/wp-content/uploads/2015/09/Collaborating-for-success.pdf

MedCity at BioJapan

Booth C-14

The MedCity delegation to BioJapan includes:

  • Dr Eliot Forster, Executive Chair, MedCity
  • Sarah Haywood, Chief Operating Officer, MedCity
  • Professor Chris Mason, Professor of Regenerative Medicine Bioprocessing, University College London
  • Professor Adrian Thrasher, Professor of Paediatric Immunology, University College London
  • Hidetoshi Hoshiya, Transactions Manager, Cell Therapy Catapult
  • Michael Bennett, Head of Transactions and Intellectual Property, Cell Therapy Catapult

UK companies joining the delegation:

  • CIMYM BioSciences
  • Curileum Discovery Ltd
  • Desktop Genetics Ltd
  • Genetic Microdevices Ltd
  • Imanova Ltd
  • Kanteron Systems
  • Plasticell LTD

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda (TSE: 4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website: www.takeda.com.

Takeda Cambridge: www.takedacam.com

About UCL (University College London)

UCL was founded in 1826. We were the first English university established after Oxford and Cambridge, the first to open up university education to those previously excluded from it, and the first to provide systematic teaching of law, architecture and medicine. We are among the world's top universities, as reflected by performance in a range of international rankings and tables. UCL currently has over 35,000 students from 150 countries and over 11,000 staff. Our annual income is more than £1 billion.

www.ucl.ac.uk

About MedCity

Established by the Mayor of London with the capital’s three Academic Health Science Centres - Imperial College Academic Health Centre, King’s Health Partners, and UCL Partners - MedCity is a unique collaboration that brings together the outstanding life sciences strengths of London and the greater south east.

Over the next 20 years, MedCity will position the region as a world-leading, interconnected hub for research, development, manufacturing and commercialisation by championing collaboration and entrepreneurship, promoting a joined up and globally distinct life sciences offer, and providing a visible ‘go-to’ point for industry and investors.

www.medcityhq.com

Contact information

MedCity
Abigail Smith
Media & PR Manager
Tel: +44 (0)20 7914 604 027
Email: abigailcsmith@medcitylondon.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

IDEMIA and Octo Telematics Reinvent Car Sharing Experience by Adding Facial Recognition to EasyOpen Solution23.2.2018 15:57Pressemelding

IDEMIA, the global leader in Augmented Identity for an increasingly digital world, announces today that it has implemented facial recognition technology on EasyOpen, a solution previously developed with its partner Omoove, a wholly-owned Octo Telematics company, Europe’s leading Shared Mobility technology provider. The digital enrolment process combined with facial recognition technology will securely enroll and authenticate the driver before EasyOpen automatically opens the car. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180223005506/en/ (Photo: Idemia) You will never rent a car the same way thanks to EasyOpen solution that combines IDEMIA’s expertise in secure service enablement and Omoove’s experience in Shared Mobility platforms and on-board technology. The first version of the solution was launched last year and allows drivers, who have already registered on the application, to use their smartphones as a key to open

SM-Optics Unveils First FLEXSET Chip, Paving the Way to Optical Micro Nodes23.2.2018 14:00Pressemelding

SM-Optics launches FLEXSET, a single chip embedding multiple processing functionalities raising the bar for performances, density and architectural flexibility. The FLEXSET is the heart of the Lightmode product family. FLEXSET OTN switching matrix scales from 300Gbps to 1Tbps and can be addressed by ports spanning from traditional low-speed services like 2Mbps over micro-OTN, to layer2 and layer3 over ODUFlex, 100G over ODU4 and 200G over FlexO. Thanks to its embedded capabilities including multi-technology OAM, packet processing, synchronization and fast protection functions, FLEXSET operates by design at the lowest latency performances and features an Intel Stratix 10 FPGA. Following the launch of micro-OTN, a revolutionary approach to efficiently extend OTN protocol to low speed services, the launch of FLEXSET advances the vision of a highly interconnected metro network and of micro nodes. Revolving around functional block elements, micro nodes collapse in few rack units OTN and pho

Bitcoin Miner HashGains’ Crowdsale to Build Green Cloud Mining Data Centers Receives Excellent Response23.2.2018 13:56Pressemelding

HashGains.com, a leading cryptocurrency mining platform, has launched its crowdsale program to build mega cryptocurrency cloud mining data centers in India and Canada which uses renewable energy like wind and solar as source of energy. “With the growing worries around bitcoin mining causing environmental damage, difficulty levels of mining increasing and returns heading southwards, there was no better opportunity but to build green energy data centers which run on free sources of energy like wind and solar, ensuring handsome mining rewards while taking care of environment,” said Mr Anuj Bairathi, CEO & Founder, HashGains, who is crypto enthusiast himself. HashGains is a growing cloud mining platform with more than 10,000 active customers enjoying mining returns and is expected to reach the mark of 1 million customers by 2020. To handle such a massive growth and ever growing demand of customers, it becomes even more important that mega mining centers are planned which can serve needs of

Stratecast Recognizes CARDINALITY as a “10 to Watch in 2018”23.2.2018 13:07Pressemelding

In their new report, “Digital Transformation Means New Tools for New Business” —part of the Global Operations, Orchestration, Data Analytics, and Monetisation (ODAM) stream—Stratecast recognises CARDINALITY for their new approach towards processing big data to deliver applications such as Customer Experience, Operational Intelligence, Network Analytics, Churn Management and Marketing Intelligence. Stratecast identified that the CARDINALITY Perception Platform brings large amounts of data from multiple CSP sources together in order to address a growing group of data analysis needs from different operational work teams and the wider business. It also does this at ingestion rates and storage levels previously thought not practical. "Using design principals tied to microservices and containerized solution components, the platform is a major advancement in meeting CSP data analysis needs at a price untouchable by previously-defined platforms," said Karl Whitelock, Stratecast director of glo

IBC2018 Welcomes Channel 4’s Keith Underwood as Guest Chair of Content Steering Group23.2.2018 11:03Pressemelding

IBC is thrilled to announce that Keith Underwood, Director of Strategy and Technology at Channel 4, has accepted the role of Guest Chair of the Conference for IBC2018. The position involves acting as the figurehead and brand ambassador for IBC, setting the vision for the programme and increasing awareness and engagement with IBC across both traditional and converging media markets. Keith is the Channel 4 Executive Committee member responsible for strategy and corporate development, broadcast operations, content management, corporate systems and the development of Channel 4’s digital products. His achievements at the public broadcaster include the launch of All 4, Channel 4’s award-winning video on demand service that replaced 4oD in 2015. “The media industry is experiencing profound shifts in consumer behaviour, competitive dynamics, and technological innovation.” Keith Underwood said. “Relentless disruption of established business models presents new opportunities and challenges for p

SES S.A.: Full Year and Fourth Quarter 2017 Results23.2.2018 07:00Pressemelding

SES S.A. announced financial results for the year and three months ended 31 December 2017. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180222006522/en/ Full Year and Fourth Quarter 2017 Results (Photo: Business Wire) Key financial highlights Reported revenue EUR 2,035.0 million, down 1.6% (-5.2% like-for-like(1)); SES Video -3.6%(1) and SES Networks -1.9%(1) EBITDA margin 65.1% (2016: 70.2% as reported and 66.7% like-for-like(1)) Net profit of EUR 596.1 million (2016: EUR 962.7 million including EUR 495.2 million gain related to O3b consolidation) Board is proposing 2017 dividend per A share of EUR 0.80 (2016: EUR 1.34) Change (%) Change (%) EUR million FY 2017 FY 2016 Reported Like-for-like (1) Q4 2017 Q4 2016 Reported Like-for-like (1) Revenue 2,035.0 2,068.8 -1.6% -5.2% 507.8 578.7 -12.2% -8.7% EBITDA 1,324.2 1,451.5 -8.8% -7.6% 329.6 390.6 -15.6% -12.2% EBITDA margin 65.1% 66.7%(1) 64.9% 67.6%(1) Operating profit (2) 6